Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML

Over the last 50 years, there has been a steady improvement in the treatment outcome of acute myeloid leukemia (AML). However, median survival in the elderly is still poor due to intolerance to intensive chemotherapy and higher numbers of patients with adverse cytogenetics. Fadraciclib (CYC065), a n...

Descripción completa

Detalles Bibliográficos
Autores principales: Chantkran, Wittawat, Hsieh, Ya-Ching, Zheleva, Daniella, Frame, Sheelagh, Wheadon, Helen, Copland, Mhairi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192769/
https://www.ncbi.nlm.nih.gov/pubmed/34112754
http://dx.doi.org/10.1038/s41420-021-00496-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192769/
https://www.ncbi.nlm.nih.gov/pubmed/34112754
http://dx.doi.org/10.1038/s41420-021-00496-y

Ejemplares similares